30
Jun

Celgene’s $1 billion front-loaded deal to buy into Juno’s CAR-T and TCR programs–$150 million upfront and $850 million for 10% of the company’s stock at more than double the going share price–instantly and predictably spurred a backlash among some of the top analysts in the industry over the frothy figures in play.

…read more

Source: Is Celgene killing the traditional biotech partnering formula?

    

0 No comments